Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.29 Insider Own18.86% Shs Outstand115.22M Perf Week7.65%
Market Cap686.92M Forward P/E- EPS next Y-0.50 Insider Trans1.36% Shs Float94.31M Perf Month1.90%
Income-29.75M PEG- EPS next Q-0.14 Inst Own60.03% Short Float5.38% Perf Quarter31.63%
Sales64.69M P/S10.62 EPS this Y-89.90% Inst Trans0.73% Short Ratio9.79 Perf Half Y0.85%
Book/sh2.79 P/B2.12 EPS next Y-0.40% ROA-9.45% Short Interest5.08M Perf Year42.58%
Cash/sh0.83 P/C7.11 EPS next 5Y- ROE-10.86% 52W Range3.14 - 6.72 Perf YTD-4.21%
Dividend Est.- P/FCF- EPS past 5Y- ROI-8.57% 52W High-11.99% Beta-0.13
Dividend TTM- Quick Ratio4.26 Sales past 5Y70.02% Gross Margin73.18% 52W Low88.22% ATR (14)0.27
Dividend Ex-Date- Current Ratio4.26 EPS Y/Y TTM6.22% Oper. Margin-60.39% RSI (14)53.55 Volatility6.52% 4.16%
Employees95 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin-45.98% Recom1.00 Target Price9.62
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-83.57% Payout- Rel Volume0.75 Prev Close5.84
Sales Surprise-46.98% EPS Surprise-15.69% Sales Q/Q- EarningsMar 20 AMC Avg Volume518.74K Price5.91
SMA204.92% SMA50-0.34% SMA20014.02% Trades Volume388,824 Change1.20%
Date Action Analyst Rating Change Price Target Change
Nov-29-23Initiated RBC Capital Mkts Outperform $6
Apr-21-23Initiated The Benchmark Company Buy $8
Apr-13-23Initiated Craig Hallum Buy $10
Feb-22-23Initiated Cowen Outperform $10
Feb-13-23Initiated H.C. Wainwright Buy $11
Dec-20-22Initiated Truist Buy $10
Dec-16-22Initiated Credit Suisse Outperform $13
Nov-29-22Initiated SVB Leerink Outperform $6
Nov-28-22Initiated Stifel Buy $12
Feb-28-24 08:27AM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
05:03AM Loading…
Nov-14-23 05:03AM
Nov-09-23 05:55PM
Nov-02-23 08:00AM
Nov-01-23 09:00AM
Oct-31-23 04:28PM
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
05:20AM Loading…
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
May-11-23 10:55PM
May-05-23 07:14AM
May-04-23 06:26AM
08:00AM Loading…
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WChief Executive OfficerDec 12Buy5.05200,0001,010,0002,645,442Dec 13 03:25 PM
FOEHR MATTHEW WPresident and CEONov 10Buy4.2795,000405,5172,427,919Nov 13 08:00 AM
FOEHR MATTHEW WPresident and CEOAug 14Buy5.4845,000246,6002,332,919Aug 15 04:56 PM
FOEHR MATTHEW WChief Executive OfficerJun 09Buy4.52115,000519,8002,574,009Jun 12 04:47 PM
HIGGINS JOHN LDirectorMay 23Option Exercise3.689,00033,1202,471,686May 25 04:45 PM
HIGGINS JOHN LDirectorMay 23Sale4.059,00036,4502,462,686May 25 04:45 PM
HIGGINS JOHN LDirectorMay 19Option Exercise3.681,0003,6802,463,686May 23 04:12 PM
HIGGINS JOHN LDirectorMay 19Sale4.051,0004,0502,462,686May 23 04:12 PM
HIGGINS JOHN LDirectorMay 18Option Exercise3.6850,000184,0002,512,686May 19 05:03 PM
HIGGINS JOHN LDirectorMay 18Sale3.8950,000194,5002,462,686May 19 05:03 PM
FOEHR MATTHEW WChief Executive OfficerMay 12Buy3.40440,0001,496,0002,438,414May 15 04:02 PM
Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
LGND Ligand Pharmaceuticals, Inc. daily Stock Chart
IndexRUT P/E27.13 EPS (ttm)2.90 Insider Own5.84% Shs Outstand17.56M Perf Week3.73%
Market Cap1.39B Forward P/E14.05 EPS next Y5.60 Insider Trans0.37% Shs Float16.67M Perf Month7.66%
Income52.15M PEG1.36 EPS next Q0.90 Inst Own92.48% Short Float5.38% Perf Quarter36.49%
Sales131.31M P/S10.61 EPS this Y-26.85% Inst Trans-0.32% Short Ratio6.55 Perf Half Y18.90%
Book/sh39.92 P/B1.97 EPS next Y25.78% ROA6.94% Short Interest0.90M Perf Year6.47%
Cash/sh9.62 P/C8.18 EPS next 5Y20.00% ROE8.29% 52W Range49.24 - 94.57 Perf YTD10.19%
Dividend Est.- P/FCF30.90 EPS past 5Y-13.18% ROI7.38% 52W High-16.78% Beta1.05
Dividend TTM- Quick Ratio12.72 Sales past 5Y-3.89% Gross Margin67.06% 52W Low59.83% ATR (14)4.17
Dividend Ex-DateJul 02, 2010 Current Ratio14.15 EPS Y/Y TTM253.69% Oper. Margin7.48% RSI (14)54.66 Volatility9.49% 4.46%
Employees58 Debt/Eq0.01 Sales Y/Y TTM-40.20% Profit Margin39.72% Recom1.20 Target Price116.80
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q199.40% Payout0.00% Rel Volume1.26 Prev Close79.35
Sales Surprise9.58% EPS Surprise108.87% Sales Q/Q-44.22% EarningsFeb 27 BMO Avg Volume136.92K Price78.70
SMA203.90% SMA506.80% SMA20017.75% Trades Volume173,021 Change-0.82%
Date Action Analyst Rating Change Price Target Change
Apr-14-21Resumed Stephens Overweight $200
Feb-04-21Reiterated H.C. Wainwright Buy $229 → $310
Oct-06-20Initiated Barclays Overweight $156
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Feb-29-24 09:30AM
Feb-28-24 07:34AM
Feb-27-24 07:00AM
Feb-22-24 04:01PM
Feb-16-24 08:00AM
04:01PM Loading…
Feb-13-24 04:01PM
Feb-01-24 05:00PM
Jan-10-24 07:30PM
Jan-05-24 04:30PM
Dec-12-23 12:01PM
Dec-11-23 09:00AM
Dec-06-23 04:02PM
Dec-01-23 08:20AM
09:01AM Loading…
Nov-28-23 09:01AM
Nov-09-23 04:47PM
Nov-08-23 04:01PM
Nov-06-23 09:00AM
Nov-01-23 08:00AM
Oct-25-23 04:01PM
Oct-18-23 08:00AM
Oct-09-23 06:15PM
Oct-03-23 06:00PM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-26-23 05:05PM
Sep-22-23 09:00AM
Sep-21-23 09:20AM
05:17PM Loading…
Sep-18-23 05:17PM
Sep-01-23 10:02PM
Aug-08-23 04:01PM
Jul-27-23 01:30PM
Jul-25-23 04:30PM
Jul-17-23 08:59AM
Jun-29-23 09:00AM
Jun-21-23 08:00PM
Jun-09-23 09:40AM
Jun-06-23 11:40AM
Jun-05-23 11:49AM
Jun-02-23 12:39PM
Jun-01-23 11:29AM
May-30-23 07:01PM
May-25-23 05:00PM
May-24-23 09:55AM
May-17-23 01:59PM
May-16-23 09:56AM
May-12-23 12:08PM
May-11-23 12:25PM
May-08-23 12:32PM
May-06-23 10:13AM
May-05-23 10:00AM
May-04-23 05:45PM
May-02-23 08:30PM
Apr-28-23 02:04PM
Apr-27-23 09:04AM
Apr-26-23 08:00PM
Apr-24-23 04:01PM
Apr-20-23 09:55AM
Apr-19-23 08:30AM
Apr-18-23 12:56PM
Apr-17-23 01:13PM
Apr-14-23 01:48PM
Apr-13-23 06:28AM
Apr-07-23 06:40PM
Apr-06-23 10:23AM
Apr-04-23 12:02PM
Mar-22-23 07:37AM
Mar-17-23 01:24PM
Mar-09-23 08:00AM
Mar-06-23 09:00AM
Mar-03-23 05:19AM
Feb-23-23 07:49AM
Feb-22-23 08:45PM
Feb-17-23 06:30PM
Feb-16-23 08:00AM
Feb-10-23 03:44AM
Feb-06-23 04:01PM
Jan-23-23 06:37AM
Jan-11-23 11:10AM
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Espinoza OctavioChief Financial OfficerFeb 28Option Exercise56.621,26471,56429,895Feb 29 06:50 PM
Espinoza OctavioChief Financial OfficerFeb 28Sale88.4614012,38429,755Feb 29 06:50 PM
Davis Todd CCHIEF EXECUTIVE OFFICERSep 22Buy59.384,000237,52973,090Sep 25 04:44 PM
KOZARICH JOHN WDirectorMay 16Sale77.204,444343,08138,488May 18 05:18 PM
Sabba Stephen LDirectorMay 10Option Exercise0.006,408032,192May 12 03:43 PM
Sabba Stephen LDirectorMay 10Sale77.136,408494,22525,784May 12 03:43 PM
KOZARICH JOHN WDirectorMay 08Option Exercise18.826,408120,59948,621May 10 07:15 PM
KOZARICH JOHN WDirectorMay 08Sale76.566,408490,62842,213May 10 07:15 PM
Reardon AndrewSee RemarksMar 24Sale69.9230020,97716,308Mar 28 05:00 PM
Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
TECH Bio-Techne Corp daily Stock Chart
IndexS&P 500 P/E53.63 EPS (ttm)1.39 Insider Own1.03% Shs Outstand157.64M Perf Week3.85%
Market Cap11.69B Forward P/E36.51 EPS next Y2.04 Insider Trans0.00% Shs Float155.57M Perf Month5.77%
Income224.12M PEG6.96 EPS next Q0.45 Inst Own100.37% Short Float3.04% Perf Quarter17.84%
Sales1.15B P/S10.21 EPS this Y-11.43% Inst Trans1.98% Short Ratio4.31 Perf Half Y-7.30%
Book/sh12.50 P/B5.95 EPS next Y15.59% ROA8.80% Short Interest4.73M Perf Year-0.71%
Cash/sh0.86 P/C86.19 EPS next 5Y7.70% ROE11.82% 52W Range51.79 - 89.91 Perf YTD-3.60%
Dividend Est.0.25 (0.34%) P/FCF51.87 EPS past 5Y16.30% ROI8.94% 52W High-17.27% Beta1.22
Dividend TTM0.32 (0.43%) Quick Ratio3.03 Sales past 5Y12.42% Gross Margin67.23% 52W Low43.62% ATR (14)2.12
Dividend Ex-DateFeb 09, 2024 Current Ratio4.37 EPS Y/Y TTM-14.72% Oper. Margin22.66% RSI (14)61.30 Volatility2.57% 3.09%
Employees3050 Debt/Eq0.28 Sales Y/Y TTM2.25% Profit Margin19.57% Recom1.40 Target Price80.32
Option/ShortYes / Yes LT Debt/Eq0.28 EPS Q/Q-44.48% Payout18.16% Rel Volume1.02 Prev Close73.57
Sales Surprise-1.78% EPS Surprise-2.96% Sales Q/Q0.37% EarningsFeb 01 BMO Avg Volume1.10M Price74.38
SMA206.26% SMA503.07% SMA2001.32% Trades Volume1,117,212 Change1.10%
Date Action Analyst Rating Change Price Target Change
Feb-08-24Initiated Scotiabank Sector Outperform $80
Feb-02-24Downgrade Stifel Buy → Hold $65
Dec-07-23Initiated UBS Buy $80
Aug-28-23Initiated William Blair Outperform
Jan-10-23Upgrade Wells Fargo Underweight → Equal Weight $90
Dec-14-22Initiated Deutsche Bank Buy $100
Dec-12-22Upgrade Citigroup Neutral → Buy $81.25 → $100
Dec-07-22Initiated RBC Capital Mkts Sector Perform $89
Aug-25-22Initiated Credit Suisse Outperform $465
Apr-25-22Downgrade Wells Fargo Equal Weight → Underweight $370
Feb-23-24 06:15AM
Feb-13-24 08:00AM
Feb-02-24 10:47AM
Feb-01-24 12:57PM
07:51AM Loading…
Jan-29-24 07:00AM
Jan-25-24 07:00AM
Jan-24-24 07:00AM
Jan-21-24 01:16PM
Jan-16-24 07:00AM
Jan-05-24 07:00AM
07:00AM Loading…
Jan-04-24 07:00AM
Dec-21-23 07:00AM
Dec-20-23 07:00AM
Dec-14-23 07:00AM
Dec-01-23 01:32AM
Nov-27-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 07:00AM
Nov-01-23 10:44AM
Oct-31-23 07:53AM
Oct-25-23 03:42PM
10:30AM Loading…
Oct-22-23 10:30AM
Oct-20-23 05:01AM
Oct-19-23 07:00AM
Oct-16-23 07:00AM
Oct-10-23 07:00AM
Oct-03-23 09:45AM
Sep-28-23 06:00AM
Sep-27-23 07:00AM
Sep-26-23 07:00AM
Sep-25-23 07:00AM
Sep-23-23 09:00AM
Sep-19-23 02:00AM
Sep-18-23 07:32PM
Sep-08-23 11:35AM
Sep-06-23 12:04PM
Aug-28-23 07:32PM
Aug-24-23 07:00AM
Aug-21-23 01:05PM
Aug-18-23 07:32PM
Aug-15-23 07:00AM
Aug-14-23 07:00AM
Aug-08-23 12:36PM
Aug-05-23 09:49AM
Jul-28-23 05:14PM
Jul-13-23 07:00AM
Jul-10-23 07:00AM
Jun-22-23 02:55PM
Jun-16-23 11:23AM
Jun-01-23 07:00AM
May-29-23 06:47AM
May-25-23 07:00AM
May-18-23 07:00AM
May-16-23 10:45AM
May-12-23 09:07AM
May-10-23 07:00AM
May-03-23 06:30AM
May-02-23 07:00AM
Apr-19-23 07:22PM
Apr-17-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 07:00AM
Apr-11-23 06:24AM
Apr-05-23 07:00AM
Apr-03-23 07:00AM
Mar-31-23 10:36AM
Mar-27-23 06:45AM
Mar-17-23 07:15AM
Mar-15-23 07:00AM
Mar-10-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 09:58AM
Feb-26-23 08:39AM
Feb-24-23 08:40AM
Feb-22-23 07:00AM
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hippel JamesCFODec 19Option Exercise31.2647,2891,478,254104,850Dec 21 04:06 PM
Nusse RoelandDirectorAug 30Option Exercise22.4032,000716,80060,811Sep 01 04:06 PM
Nusse RoelandDirectorAug 30Sale80.328,939717,95951,872Sep 01 04:06 PM
Kelderman KimPres. Diagnostics & GenomAug 24Option Exercise47.602,10099,96021,225Aug 28 04:19 PM
Kummeth Charles R.Chief Executive OfficerAug 15Option Exercise0.0017,63201,286,944Aug 17 04:14 PM
Kummeth Charles R.Chief Executive OfficerAug 05Option Exercise0.0051,51601,310,282Aug 08 05:31 PM
Hippel JamesCFOAug 05Option Exercise0.0012,876063,896Aug 08 05:29 PM
Kelderman KimPres. Diagnostics & GenomAug 05Option Exercise0.008,060023,264Aug 08 05:28 PM
Kummeth Charles R.Chief Executive OfficerJul 21Sale88.3680,0007,069,0241,258,766Jul 25 05:27 PM
Kummeth Charles R.Chief Executive OfficerJun 30Option Exercise26.65616,67616,434,4151,729,493Jul 05 06:38 PM
Kummeth Charles R.Chief Executive OfficerJun 07Sale83.0032226,7261,112,817Jun 09 04:07 PM
HIGGINS JOHN LDirectorApr 28Option Exercise21.8516,000349,60039,360May 02 04:49 PM